Patents Assigned to BIOPROJET Pharma
  • Therapeutical use of H3-ligands
    Patent number: 11179329
    Abstract: The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: November 23, 2021
    Assignee: BIOPROJET PHARMA
    Inventors: Jeanne-Marie Lecomte, Jean-Charles Schwartz, Olivier Labeeuw, Marc Capet
  • NEW THERAPEUTICAL USE OF H3-LIGANDS
    Publication number: 20200093738
    Abstract: The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.
    Type: Application
    Filed: March 21, 2018
    Publication date: March 26, 2020
    Applicant: BIOPROJET Pharma
    Inventors: Jeanne-Marie LECOMTE, Jean-Charles SCHWARTZ, Oliver LABEEUW, Marc CAPET
  • TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    Publication number: 20200024256
    Abstract: The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3 -methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 23, 2020
    Applicant: BIOPROJET Pharma
    Inventors: Marc CAPET, Jeanne-Marie LECOMTE, Jean-Charles SCHWARTZ